Telik (TELK), biopharmaceutical company, is off almost 25% today on news that the FDA has stopped research on its ovarian cancer drug Telcyta.
Stating the obvious, Wachovia said: "Anticipating significant shareholder backlash and harsh challenge to management credibility, we believe Telik will drown in negative publicity pending FDA review of Telcyta clinical data," Thanks for the heads up, but the shares are off from a 52-week high of $20.36 to trade as low as $3.45 today.
Telik is another example of a bio company that has virtually all of its eggs in one basket. At one point, the company had a market cap of $1.5 billion. The company has brought in no revenue in the last four quarters but has lost $83 million.
Nice touch.
Douglas A. McIntyre
Sponsored: Attention Savvy Investors: Speak to 3 Financial Experts – FREE
Ever wanted an extra set of eyes on an investment you’re considering? Now you can speak with up to 3 financial experts in your area for FREE. By simply
clicking here you can begin to match with financial professionals who can help guide you through the financial decisions you’re making. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.